AHA/ASA Stroke Council Chair-elect and volunteer expert, Patrick D. Lyden, M.D., offers perspective (via Zoom) on ISC 20 presentations 11 and 114. He is Carmen and Louis Warschaw Chair in Neurology; professor, Neurology Cedars Sinai, Los Angeles, CA.
copyright American Heart Association 

"In the original study, they sort of took all commerce, and they didn't really focus on the patients most likely to benefit. What these two sub-analyses, or after-the-fact analyses have shown is that if you really pay attention to what kind of stroke the patient has, and you optimize the treatment and really personalize it to the patient, you get much better results, and it means the therapy could be much more usable for patients if you select the appropriate and most likely to benefit patient, and then do it correctly, titrate the therapy so that it works better."